Holen Sie sich die Stockscreener-App
154.38
0.08%
-0.13
Schlusskurs vom Vortag:
$154.51
Offen:
$157.1
24-Stunden-Volumen:
87,935
Relative Volume:
0.53
Marktkapitalisierung:
$6.17B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-77.61M
KGV:
-67.18
EPS:
-2.2979
Netto-Cashflow:
-
1W Leistung:
-2.74%
1M Leistung:
-9.11%
6M Leistung:
+37.32%
1J Leistung:
+147.01%
1-Tages-Spanne:
$153.48
$158.95
1-Wochen-Bereich:
$153.48
$160.24
52-Wochen-Spanne:
$56.10
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
154.38 | 6.18B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-26 | Eingeleitet | BofA Securities | Buy |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-02 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Eingeleitet | Mizuho | Neutral |
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares - Investing.com
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS - Stock Titan
Belite Bio CSO Nathan Mata sells $155,777 in shares By Investing.com - Investing.com South Africa
Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160 - Stock Titan
Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus - Barchart
Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under 10b5-1 plan - Stock Titan
Belite bio CSO Nathan Mata sells $159,162 in shares - Investing.com
Belite bio CSO Nathan Mata sells $159,162 in shares By Investing.com - Investing.com India
Belite Bio (BLTE) CSO sells 1,000 ADS in planned open-market trades - Stock Titan
A Look At Belite Bio (BLTE) Valuation As Tinlarebant NDA Submission Progresses - Sahm
Belite Bio (NASDAQ:BLTE) Insider Sells $162,640.00 in Stock - MarketBeat
Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares - Investing.com India
Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares By Investing.com - Investing.com South Africa
Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor ConferenceSlideshow - Seeking Alpha
Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference - MarketBeat
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, Apr-28-2026 09 - marketscreener.com
Belite Bio (NASDAQ:BLTE) Insider Sells $159,560.00 in Stock - MarketBeat
Belite Bio chief scientific officer Nathan Mata sells $159,555 in stock - Investing.com India
Belite Bio (BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit - The Manila Times
Belite Bio CSO Nathan Mata sells $166,283 in shares By Investing.com - Investing.com Australia
Belite Bio CSO Nathan Mata sells $166,283 in shares - Investing.com
Belite Bio (BLTE) CSO sells 1,000 ADS in Rule 10b5-1 trades - Stock Titan
Belite Bio CSO Nathan Mata sells $170,384 in shares By Investing.com - Investing.com South Africa
Belite Bio CSO Nathan Mata sells $170,384 in shares - Investing.com
BELITE BIO (BLTE) CEO gains 10,000 shares from vested RSUs - Stock Titan
[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan
Belite Bio (BLTE) CFO RSUs vest into 10,000 ordinary shares - Stock Titan
Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com
Four Belite Bio conference appearances are set from April 28 to May 26 - Stock Titan
Belite Bio chief scientific officer sells $166,000 in shares By Investing.com - Investing.com Canada
Belite Bio chief scientific officer sells $166,000 in shares - Investing.com
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS disclosed - Stock Titan
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks - TipRanks
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th - marketscreener.com
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - MarketBeat
Belite Bio begins rolling NDA submission for Stargardt treatment By Investing.com - Investing.com India
Belite Bio CSO Nathan Mata sells $163,594 in shares By Investing.com - Investing.com Canada
Belite Bio CSO Nathan Mata sells $163,594 in shares - Investing.com
Belite Bio begins rolling NDA submission for Stargardt treatment - Investing.com
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease - TipRanks
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):